|
Repurposing a Potent MDM2 Inhibitor for Leukemia Treatment
Application
VERU-111, also known as sabizabulin, is a potent microtubule inhibitor and, notably, an MDM2 inhibitor. This repurposed compound demonstrates remarkable efficacy in the treatment of Acute Myeloid Leukemia (AML).
Key Benefits
Unique dual-action functionality as a microtubule and MDM2 inhibitor.
Successful inhibition of MDM2, an oncogene...
Published: 4/11/2024
Contributor(s): Deborah DeRyckere, Muxiang Zhou, Lu Bing Gu, Douglas Graham, Tao Liu
|
|
Liposome Encapsulated Tyrosine Kinase Inhibitors to Treat Leukemia
Application
Lipid encapsulation of MRX-2843 for the treatment of leukemia.
Key Benefits
Encapsulation of a tyrosine kinase inhibitor called MRX-2843 within a liposome improves its performance in an animal model of acute lymphoblastic leukemia.
Systemic delivery of this therapeutic requires a lower dose and less frequent administration than oral...
Published: 4/8/2024
Contributor(s): Erik Dreaden, James Kelvin, Deborah DeRyckere, Douglas Graham, Juhi Jain
|
|
Cell and Gene Therapies for Hemophagocytic Lymphohistiocytosis
Application
Gene/cell therapy to treat hemophagocytic lymphohistiocytosis.
Key Benefits
Gene therapy approach for treating patients with UNC13D mutated hemophagocytic lymphohistiocytosis.
Preliminary in vitro and in vivo data show the ability of the gene therapy to increase UNC13D protein levels and decrease T cell activation.
It is administered...
Published: 1/17/2024
Contributor(s): H. (Harold) Trent Spencer, Christopher Doering, Shanmuganathan Chandrakasan, Sarah Takushi
|
|
Machine Learning Diagnostic for Automated Identification and Classification of Bone Marrow Cells
Application
Assist in the diagnosis of hematologic disorders of bone marrow.
Key Benefits
Automated machine learning approach for performing bone marrow differential counts that accounts for all viable cells on the smear.
Preliminary data generated by a prototype shows the system is fast and demonstrates precision compared to manual counting.
Potential...
Published: 1/10/2024
Contributor(s): David Jaye, Lee Cooper, Joshua Lewis, David Gutman
|
|
Antisense Oligonucleotides Therapeutics Targeting Specific Tissues or Cells
Application
Antisense oligonucleotide (ASO) therapies for the treatment of rare diseases and cancer.
Key Benefits
Novel approach to ASO therapeutics that potentially improve tissue/cell targeting capabilities.
Increases the efficacy of ASOs while decrease off-target toxicity.
Potential to treat a variety of genetic diseases such as cancer, blood...
Published: 4/8/2024
Contributor(s): Jiahui Zhang, Khalid Salaita, Hanjoong Jo
|
|
Central Line-Associated Bloodstream Infection (CLABSI) Prediction Model
Application
A predictive model of central line-association bloodstream infection (CLABSI).
Key Benefits
Specifically designed to improved predictive analysis of patients who are at risk for CLABSI.
Scored higher predictive values on average than similar predictive modeling without the hypotheses driven approach (Bidirectional LSTM with...
Published: 7/28/2023
Contributor(s): Azade Tabaie, Rishikesan (Rishi) Kamaleswaran, Evan Orenstein
|
|
Additives that Increase Storage and Shelf Life of Platelets
Application
Monoclonal antibody additive that inhibits ectodomain shedding of a platelet glycoprotein to improve platelet storage.
Key Benefits
Current storage techniques allows for limited storage times (5-7 days).
New additive may enable platelet storage at 4°C, increase platelet storage time, and improve quality of stored platelets.
Inhibits...
Published: 3/11/2024
Contributor(s): Renhao Li
|
|
Micron-Sized Drug Vehicle for Unregulated Blood Clotting
Application
Fibrinogen-coated micron-sized drug vehicles for targeted treatment of unregulated blood clotting.
Key Benefits
Facilitates targeted release of drugs specifically for blood clotting disorders.
Drug delivery vehicle can be used with newly discovered or known therapeutics on the market.
Site specific biological mechanism may help increase...
Published: 4/10/2024
Contributor(s): Caroline Hansen, Yumiko Sakurai, Wilbur Lam, Andrew Lyon
|
|
Microfluidic Device Enhances Understanding of Clot Formation
Application
A microfluidic device for the measurement and quantification of the mechanical forces that occur during clot formation for use in hematology research or for diagnostic purposes.
Key Benefits
Is capable of measuring platelet-platelet interactions at the single cell level that is not possible with current tools.
Facilitates quick &...
Published: 11/6/2023
Contributor(s): David Myers, Wilbur Lam, Yongzhi Qiu
|
|
Algorithm and Software Application for the Diagnosis of Adverse Reactions to Blood Transfusion
Application
Web-based and mobile application based on the National Healthcare Safety Network’s Biovigilance Component Hemovigilance Module Surveillance Protocol to aid in the identification of adverse reactions to transfusions easily and accurately.
Key Benefits
Provides a quick, easy, and accurate method to identify transfusion reactions...
Published: 7/28/2023
Contributor(s): John Roback, Geoffrey Smith
|